These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 26367725)

  • 1. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
    Kotrych D; Dziedziejko V; Safranow K; Pawlik A
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
    Milic V; Jekic B; Lukovic L; Bunjevacki V; Milasin J; Novakovic I; Damnjanovic T; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Pejnovic N; Krajinovic M
    Clin Exp Rheumatol; 2012; 30(2):178-83. PubMed ID: 22324981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of allograft inflammatory factor-1 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.
    Pawlik A; Herczynska MM; Dziedziejko V; Malinowski D; Kurzawski M; Drozdzik M; Gawronska-Szklarz B
    Postepy Hig Med Dosw (Online); 2013 Jul; 67():637-42. PubMed ID: 24018427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis.
    Kotrych D; Dziedziejko V; Safranow K; Drozdzik M; Pawlik A
    Rheumatol Int; 2015 Aug; 35(8):1319-23. PubMed ID: 25702175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ESR1 and ESR2 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.
    Pawlik A; Dziedziejko V; Kurzawski M; Safranow K; Kotrych D; Bohatyrewicz A
    Pharmacol Rep; 2012; 64(1):185-90. PubMed ID: 22580535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.
    Yellin M; Paliienko I; Balanescu A; Ter-Vartanian S; Tseluyko V; Xu LA; Tao X; Cardarelli PM; Leblanc H; Nichol G; Ancuta C; Chirieac R; Luo A
    Arthritis Rheum; 2012 Jun; 64(6):1730-9. PubMed ID: 22147649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
    Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
    Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
    Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
    Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.
    Lima A; Seabra V; Bernardes M; Azevedo R; Sousa H; Medeiros R
    PLoS One; 2014; 9(10):e108165. PubMed ID: 25279663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.
    Soukup T; Dosedel M; Pavek P; Nekvindova J; Barvik I; Bubancova I; Bradna P; Kubena AA; Carazo AF; Veleta T; Vlcek J
    Rheumatol Int; 2015 Jul; 35(7):1149-61. PubMed ID: 25618758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Nov; 36(11):1591-1599. PubMed ID: 27379764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.
    Chaabane S; Marzouk S; Akrout R; Ben Hamad M; Achour Y; Rebai A; Keskes L; Fourati H; Bahloul Z; Maalej A
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):385-93. PubMed ID: 26077125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
    Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
    J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
    Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
    Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS
    Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients.
    Vejnović D; Milić V; Popović B; Damnjanović T; Maksimović N; Bunjevački V; Krajinović M; Novaković I; Damjanov N; Jekić B
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):253-257. PubMed ID: 30583708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.